Opinion: As the COVID emergency ends, monoclonal antibodies remain essential

As the COVID emergency ends, monoclonal antibodies remain essential With the FDA not currently approving mAbs and the federal government no longer buying them, monoclonals seem to have been expunged from America’s COVID-fighting strategy. dtodd The Hill

...

Monoclonal antibodies (mAbs) — laboratory-grown proteins that work like natural antibodies to help the body fight illness — have been a valuable tool for treating COVID in this population. Monoclonal products such as bamlanivimab, casirivimab and imdevimab (which are administered together) and sotrovimab were found to be particularly beneficial in reducing the risk of hospitalization and death for the estimated 3 percent of Americans with weakened immune systems. In addition to reducing the severity of infections, mAbs have been shown to help prevent COVID among the immunocompromised and in the general population.  

...